Table 1.
miRNA | Tissue | Clinicopathological characteristics associated with deregulated miRNA expression | Target | Ref. | |
---|---|---|---|---|---|
Downregulated | 26a | GBC | Advanced histologic grade | HMGA2 | [62] |
34a | EHC, GBC | Poor disease-free and overall survival; increased telomere length; advanced clinical stage; lymph node metastasis | PNUTS, SMAD4 | [39, 40] | |
101 |
GBC |
Enhanced tumor size; enhanced tumor invasion; higher TNM stage; poor survival | [78] | ||
122 | Increased expression of PKM2 | PKM2 | [77] | ||
124 | IHC | SMYD3 | [68] | ||
135a-5p | GBC | Advanced histologic grade | VLDLR | [72] | |
138 | Increased expression of BAG-1 | BAG-1 | [79] | ||
144 | CC | Increased expression of LIS1 | LIS1 | [66] | |
145 | GBC | Poor survival | MRP | [70] | |
200 family | CC | SUZ12, ROCK2 | [56] | ||
204 | IHC | Lymph node metastasis | SLUG | [53] | |
214 | Enhanced metastatic potential | TWIST | [54] | ||
370 | CC | WNT10B | [80] | ||
373 | hCC | Poor cell differentiation; advanced clinical stage | MBD2 | [63] | |
605 | IHC | PSMD10 | [43] | ||
| |||||
Upregulated | 20a | GBC | Local invasion; distant metastasis; poor prognosis and survival | SMAD7 | [81] |
21 | CC, IHC | Poor disease-free and overall survival; higher clinical stage at diagnosis; poor cell differentiation; lymph node metastasis | 15-PGDH, PDCD4, TIMP3, PTPN14, PTEN | [82–85] | |
26a | CC | GSK-3β | [86] | ||
92a | PTEN | [87] | |||
141 | BTC | Shorter disease-free and overall survival; greater risk of angiolymphatic invasion | [88] | ||
155 | GBC | Shorter disease-free survival; lymph node metastasis; vessel invasion | [89] | ||
221 | EHC | Shorter disease-free survival; advanced clinical stage | PTEN | [90] |
CC: cholangiocarcinoma; EHC: extrahepatic cholangiocarcinoma; GBC: gallbladder carcinoma; hCC: hilar cholangiocarcinoma; IHC: intrahepatic cholangiocarcinoma; miRNA: microRNA.